400
Participants
Start Date
December 1, 2002
Study Completion Date
December 1, 2005
Alefacept
Hospital Cantonal, Geneva
Hopital L'Archet II, Nice
New York University School of Medicine, New York
Humboldt Universitätsklinikum Charité, Berlin
Universitätskrankenhaus Eppendorf, Hamburg
Virginia Clinical Research, Inc., Norfolk
Wake Forest University School of Medicine, Winston-Salem
Duke University Medical Center, Durham
Universitäts Kliniken, Göttingen
Heinrich-Heine-Universität, Düsseldorf
St. Josef-Hospital, Bochum
Universitätsklinikum Münster, Münster
Loyola University Medical Center, Maywood
J W Goethe Universität, Frankfurt
Central Dermatology, St Louis
Universitätskliniken des Saarlandes, Homburg/Saar
Universität Mannhein, Mannheim
Hopital Lyon Sud, Pierre-Bénite
Baylor Dermatology Research Center, Dallas
Hospital Saint Louis, Université Paris VII, Paris
MD Anderson Cancer Center, Houston
Klinikum der Albert-Ludwig-Universität, Freiburg im Breisgau
University of Utah School of Medicine, Salt Lake City
Clinical Research Specialists, Inc., Santa Monica
University of California, Irvine, Irvine
CHU Henri Mondor, Créteil
University of California, San Francisco, San Francisco
Dermatology Associates, Seattle
University of Connecticut Health Center, Farmington
Massachusetts General Hospital, Boston
University of Medicine and Dentistry Robert Wood Jonhson Medical School, New Brunswick
The Mount Sinai School of Medicine, New York
University Hospitals of Cleveland, Cleveland
Rivergate Dermatology, Goodlettsville
University of Vienna, Vienna
Western Canada Dermatology Institute, Edmonton
Vancouver Hospital, Vancouver
Eastern Canada Cutaneous Research Associates, Halifax
Dermatrials Research, Hamilton
Royal Victoria Hospital, Montreal
Marselisborg Hospital, Aarhus C
Universitätsklinikum Carl Gustav Carus, Dresden
AMC University of Amsterdam, Amsterdam
University Hospital Nijmegen - St. Radboud, Nijmegen
St. John's Institute of Dermatology, London
Academic Dermatology, Salford
Lead Sponsor
Biogen
INDUSTRY